STERIS PLC

STE

Equity

ISIN IE00BFY8C754 / Valor 47027903

New York Stock Exchange, Inc (2025-11-17)

USD 257.01-0.54%

STERIS PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

STERIS PLC, originally founded as Innovative Medical Technologies in Ohio in 1985 and renamed in 1987, has grown into a leading global provider in infection prevention and procedural products and services. With a history enriched by acquisitions, such as the American Sterilizer Company, STERIS now boasts a workforce of approximately 16,000 associates and operates in over 100 countries. The company's portfolio spans a broad range of innovative capital equipment, including sterilizers, washers, surgical tables, and lights, alongside equipment management systems and connectivity solutions aimed at integrating operating rooms. Additionally, STERIS offers a variety of consumable products, from detergents to gastrointestinal endoscopy accessories and dental instruments. Its service offerings are comprehensive, covering equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory services, and off-site reprocessing. Central to STERIS's mission is its commitment to supporting patient care by focusing on infection prevention, thereby aiding healthcare, life sciences, and dental sectors in creating healthier and safer environments.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

For the full year fiscal 2025, STERIS PLC's revenue from continuing operations rose by 6% to $5.5 billion compared to $5.1 billion in fiscal 2024. In the fourth quarter alone, revenue increased by 4% to $1.5 billion from $1.4 billion in the same period last year, with constant currency organic revenue growth maintaining a steady 6%.

Earnings Improvement

The company reported a full-year diluted EPS from continuing operations of $6.16, up from $5.55 in fiscal 2024. Adjusted EPS saw an increase to $9.22, reflecting enhanced profitability. In the fourth quarter, adjusted net income per diluted share grew to $2.74 from $2.41 year-over-year.

Segment Performance

Healthcare revenue grew by 5% in the fourth quarter to $1.1 billion, driven by a 13% improvement in service revenue and a 6% increase in consumables, partially offset by a 4% decline in capital equipment. Applied Sterilization Technologies (AST) saw a 9% revenue rise to $273.9 million, with a 10% constant currency organic growth. Conversely, Life Sciences experienced a 7% revenue decrease to $149.5 million, primarily due to the divestiture of the CECS business and a decline in capital equipment revenue.

Cash Flow

STERIS PLC generated $1.15 billion in net cash from operations for fiscal 2025, up from $973.3 million in the previous year. Free cash flow also increased to $787.2 million, driven by improvements in working capital.

Fiscal 2026 Outlook

The company projects a 6-7% increase in revenue from continuing operations for fiscal 2026, with constant currency organic revenue growth expected to be in the same range. Adjusted earnings per diluted share are anticipated to rise by 7-10% to between $9.90 and $10.15. Capital expenditures are forecasted at approximately $375 million, with free cash flow expected around $770 million.

Summarized from source with an LLMView Source

Key figures

16.8%1Y

54.8%3Y

31.7%5Y

Performance

22.9%1Y

24.5%3Y

25.6%5Y

Volatility